Please assess the completion status of the following clinical trial:

Trial Title: Sayana® Press Extension Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* not pregnant and no desire to become pregnant in the next 18 months~* regular menstrual cycles (25 to 35 days in length when not using hormonal contraception, pregnant, or lactating)~* at risk of pregnancy (no diagnosis of infertility, no history of tubal ligation or hysterectomy, and an average of 1 or more unprotected acts of vaginal intercourse per month)~* in good general health as determined by a medical history~* 18 to 35 years of age, inclusive~* willing to provide informed consent, follow all study requirements, and rely on Sayana® Press injected every 4 months as the only means of contraception for 12 months~* has only one sexual partner and expects to have that same sexual partner for the next 12 months~Exclusion Criteria:~* has a primary partner who has received a vasectomy or is otherwise sterile~* medical contraindications to depot medroxyprogesterone acetate (DMPA) per World Health Organization medical eligibility criteria for contraceptive use~* known HIV-infection (for her or her partner)~* diagnosis or treatment for a sexually transmitted infection in the past month (for her or a partner), excluding recurrent herpes or condyloma~* received an injection of a progestin-only containing contraceptive (DMPA or norethisterone enanthate) in the past 12 months~* received an injection of a combined injectable contraceptive in the past 6 months~* known or suspected allergic reaction to DMPA~* used a levonorgestrel-releasing intrauterine system, NuvaRing, contraceptive patch, oral contraceptives or a contraceptive implant in the 7 days prior to enrollment (PK cohort only)~* previous (within 1 month prior to enrollment), current or planned (in the next 12 months) use of an investigational drug, prohibited drug per protocol or other drug which in the opinion of the site investigator could complicate study findings~* has been pregnant in the past month~* is lactating~* plans to move to another location in the next 12 months~* has a social or medical condition which in the opinion of the site investigator would make study participation unsafe, or interfere with adherence to protocol requirements.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Abdomen (Type: EXPERIMENTAL): Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
- Upper thigh (Type: EXPERIMENTAL): Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
- Back of the upper arm (Type: EXPERIMENTAL): Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete